Québec City, Canada, February 8, 2024 — Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, announces …

Using the Feldan Shuttle technology, our team and collaborators have successfully demonstrated for the first time, the feasibility of base editing in non-human primate lungs. This study provides in vivo …

Québec City, Canada, October 3, 2023 - Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, is …

Feldan is proud to announce that it will receive advisory services and up to $563,000 in funding from the National Research Council Canada, Industrial Research Assistance Program (NRC- IRAP) for …

Feldan is awarded an Applied Research and Development grant via the College and Community Innovation (CCI) program, for a total amount of $450,000. This funding will help develop Feldan Shuttle …

MONTREAL, April 18, 2023 – CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat …

Feldan Therapeutics is pleased to share the promising results of FLD103 to treat basal cell carcinoma. A poster presented at the WCH23 Dermatology Conference last January (Intralesional Treatment of Basal …

Quebec City, Canada, January 18, 2022 - Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the …

Read more on pages 54 to 57: BIOTECanada Insights sping 2021 …

Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. Feldan is honoured to be part of this …